collaboration
Hummingbird Bioscience, Novogene Partner to ID Cancer Patients With NRG1 Fusions in China
Novogene will use next-generation sequencing to identify solid tumor patients eligible to enroll in clinical trials of Hummingbird's anti-HER3 agent, HMBD-001.
Vela Diagnostics, National Cancer Center of Singapore to Develop CDx for EGFR-TKI Therapies
Vela Diagnostics and NCCS will evaluate the efficacy of the assay in a clinical trial to test the response of patients to EGFR-TKI therapies.
Rain Therapeutics, Tempus Partner to Identify Patients with MDM2-Amplified Tumors for Basket Trial
Tempus will provide centralized DNA and RNA tumor sequencing to help Rain enroll patients in a Phase II trial for its MDM2 inhibitor.
Oncocyte, Italian Foundation to Investigate DetermaIO in Colorectal Cancer
The Italian research group will evaluate the ability of Oncocyte's gene expression assay in samples from immunotherapy trials for advanced colorectal cancer patients.
Rain Therapeutics Partners With Caris to Enroll Patients for MDM2 Inhibitor Basket Trial
Caris will perform whole-exome and whole-transcriptome sequencing to identify patients with MDM2-amplified solid tumors eligible to enroll in the study.